We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response.
- Authors
Penghui He; Haifeng Wan; Juan Wan; Hanyu Jiang; Yu Yang; Kunlin Xie; Hong Wu
- Abstract
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third most common cause of cancer-related death worldwide. Due to asymptomatic patients in the early stage, most patients are diagnosed at an advanced stage and lose the opportunity for radical resection. In addition, for patients who underwent procedures with curative intent for early-stage HCC, up to 70% of patients may have disease recurrence within 5 years. With the advent of an increasing number of systemic therapy medications, we now have more options for the treatment of HCC. However, data from clinical studies show that with different combinations of regimens, the objective response rate is approximately 40%, and most patients will not respond to treatment. In this setting, biomarkers for predicting treatment response are of great significance for precise treatment, reducing drug side effects and saving medical resources. In this review, we summarized the existing and emerging biomarkers in the literature, with special emphasis on the pathways and mechanism underlying the prediction value of those biomarkers for systemic treatment response.
- Subjects
HEPATOCELLULAR carcinoma; DRUG side effects; ASYMPTOMATIC patients; BIOMARKERS; DISEASE relapse
- Publication
Frontiers in Oncology, 2022, Vol 12, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2022.1015527